Man Group
IMCR icon

Man Group’s Immunocore IMCR Stock Holding History

Man Group’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,900
Closed -$418K – 2089
2022
Q3 		$418K Buy
+8,900
New +$424K ﹤0.01% 1571

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Man Group's IMCR Position: Q4 2022 in Review

Man Group sold out of Immunocore (IMCR) in Q4 2022, closing a stake of 8,900 shares — an estimated $418K sold.

Man Group first reported a position in IMCR in Q3 2022 and held it in 1 quarter. The position peaked at $418K in Q3 2022. 104 funds tracked by Wall St. Rank hold IMCR as of Q4 2022.

  • Man Group reported no remaining Immunocore position as of Q4 2022 after selling out during the quarter.
  • Man Group sold 8,900 Immunocore shares in Q4 2022, an estimated $418K.
  • Man Group first reported a position in Immunocore in Q3 2022 and held it in 1 quarter.
  • Man Group's Immunocore position peaked at $418K in Q3 2022.
  • 104 funds tracked by Wall St. Rank held Immunocore as of Q4 2022.

Based on Man Group's 13F filing for Q4 2022, filed 14 Feb 2023.